Medication governance in SA workers' compensation

ReturnToWorkSA framework, legislative requirements, and medication management best practices

Published: 2026-04-03

Introduction

South Australia's workers compensation system is administered by ReturnToWorkSA under the Return to Work Act 2014. Within this framework, medication governance is essential for managing costs, ensuring appropriate treatment, and supporting effective return-to-work outcomes. This article outlines the regulatory framework for medication management, ReturnToWorkSA guidance, and best practice approaches to medication governance in South Australian workers compensation claims.

The South Australian legislative framework

The Return to Work Act 2014

The Return to Work Act 2014 (SA) establishes South Australia's workers compensation framework. The Act requires that workers injured in the course of employment are entitled to reasonable and necessary medical and pharmaceutical treatment. The Regulation specifies scope of coverage, requirements for approval of medical services, and the process for managing treatment disputes.

ReturnToWorkSA's regulatory role

ReturnToWorkSA administers the workers compensation scheme and provides guidance to self-insured employers and insurers on compliance with the Return to Work Act. ReturnToWorkSA's guidance supports effective claims management, cost control, and return-to-work outcomes. Medication governance is an important component of effective claims management.

The Return to Work Coordinator role

Under the Return to Work Act, a Return to Work Coordinator (often the claims manager or a designated coordinator) is responsible for coordinating treatment and supporting return to work. The Coordinator can approve or decline treatment, including medications. Best practice involves collaborative decision-making with the treating doctor.

Key medication governance issues in South Australia

Reasonable and necessary treatment assessment

The central governance issue is determining whether prescribed medications are "reasonable and necessary" for management of the work-related condition. This assessment requires consideration of clinical appropriateness, evidence base, cost-effectiveness, and alignment with the return-to-work goal. Disputes frequently arise over this assessment.

Return-to-work integration

South Australia's scheme emphasises return to work as a key outcome. Medication governance should support return-to-work by ensuring medications facilitate recovery and functional improvement. Medications that impede return to work (e.g., high-dose opioids affecting cognition) may require modification or deprescribing as part of the return-to-work strategy.

High-cost medication management

Specialty medications and high-cost therapies require careful governance. ReturnToWorkSA expects insurers to manage high-cost medications through prior approval processes, cost-benefit analysis, and identification of lower-cost alternatives where clinically appropriate.

Chronic medication management

Claims extending over months or years often involve chronic medication use. Governance requires regular monitoring of medication regimens, assessment of ongoing appropriateness, and deprescribing where medications are no longer indicated or support return to work.

ReturnToWorkSA-endorsed best practices

Medication governance frameworks for South Australian insurers

Reasonable and necessary treatment approval

Clear procedures for assessing whether treatment is "reasonable and necessary" reduce disputes. Procedures should specify the criteria for approval, the evidence required to demonstrate reasonableness and necessity, and the process for reviewing disputed treatment requests.

Prior approval for high-cost medications

High-cost medications may require prior approval before initiation. Procedures should specify when approval is required, the approval process, and the timeline for approval decisions. Early pharmacist review can support approval decisions.

Monitoring and review protocols

Claims should include protocols for regular review of medication regimens. Reviews should assess whether medications continue to be reasonable and necessary, whether they support return to work, and whether deprescribing or modification is appropriate.

Return-to-work integration

Medication governance should be integrated into return-to-work planning. Medications should be optimised to support functional improvement and return to work. Deprescribing or medication modification should be considered as part of the return-to-work strategy.

Special considerations for South Australia

Self-Insured Employers

Self-insured employers have direct responsibility for medication governance. Clear procedures and documentation in self-insured schemes' medication policies support consistent governance across claims.

Focus on Return to Work Outcomes

ReturnToWorkSA places significant emphasis on return-to-work outcomes. Medication management should be evaluated not only for appropriateness and cost, but also for support of return-to-work objectives. Medications that impede return to work should be flagged for modification.

Conclusion

Medication governance in South Australia's workers compensation scheme requires assessing whether medications are reasonable and necessary for managing the work-related condition and supporting return to work. ReturnToWorkSA guidance supports pharmacist-led medication review, early optimization, therapeutic guideline alignment, and integration with return-to-work planning. By implementing best practice medication governance frameworks aligned with return-to-work objectives, South Australian insurers can improve claimant outcomes, manage costs, and achieve better return-to-work results. Pharmacist-led medication review is a key tool in achieving ReturnToWorkSA-endorsed medication governance and return-to-work outcomes.